We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    natural immunogenics
Previous Study | Return to List | Next Study

A Study Investigating the Safety and Efficacy of Bio-Active Silver Hydrosol™ in Providing Immune Support

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04144673
Recruitment Status : Completed
First Posted : October 30, 2019
Last Update Posted : April 23, 2021
Sponsor:
Collaborator:
KGK Science Inc.
Information provided by (Responsible Party):
Natural Immunogenics Corp.

Brief Summary:
The objective of this study is to investigate the ability of Bio-Active Silver Hydrosol™ in providing immune support in healthy adult males and females participating in intense aerobic exercise. Sixty eligible participants are planned to be randomized into either the investigational product or treatments arms and will consume the study product for 60 days (check-in visit on day 28). Questionnaires will be completed and blood and saliva samples will be collected to measure the endpoints.

Condition or disease Intervention/treatment Phase
Healthy Other: Silver Hydrosol Other: Placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, double-blind, placebo-controlled, parallel study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Other
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Safety and Efficacy of Bio-Active Silver Hydrosol™ in Providing Immune Support
Actual Study Start Date : November 14, 2019
Actual Primary Completion Date : June 1, 2020
Actual Study Completion Date : June 1, 2020

Arm Intervention/treatment
Experimental: Investigational Product Other: Silver Hydrosol
Silver quantity will be 7 doses per day, with 50 mcg per dose.
Other Name: Sovereign Silver, Bio-Active Silver Hydrosol™

Placebo Comparator: Placebo Other: Placebo
Placebo water with no active ingredients




Primary Outcome Measures :
  1. The difference between Bio-Active Silver Hydrosol™ and placebo in the mean global severity index, as measured by area under the curve (AUC) for the WURSS-24 daily symptom scores after 60 days supplementation. [ Time Frame: 60 days ]
    The Wisconsin Upper Respiratory Symptom Survey (WURSS) is a questionnaire used to evaluate the negative impact of acute URTIs. The WURSS-24 contains 24 items scored on a Likert-type severity scale. It contains the same items as the WURSS-21 along with headache, body ache, and fever to capture influenza-like illness symptoms. The items are scored on a 0 (do not have this symptom) to 7 (severe) scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Provided voluntary, written, informed consent to participate in the study
  2. Females and males between 19 and 65 years of age inclusive
  3. Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening Or,

    1. Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
    2. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
    3. Double-barrier method
    4. Intrauterine devices
    5. Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
    6. Vasectomy of partner at least 6 months prior to screening
  4. BMI between 18.5 to 29.9 kg/m2 inclusive
  5. Individuals participating in an intense aerobic sport (e.g. cycling, running, triathlon, swimming, soccer, Nordic skiing, basketball, hockey, gym etc.) for greater than or equal to 5 hours a week
  6. Agrees to provide a verbal history of flu vaccination
  7. Healthy as determined by laboratory results, medical history, and physical exam or as determined by the QI
  8. Agrees to maintain current diet and exercise programs
  9. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits

Exclusion Criteria:

  1. Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial
  2. Subject has a known allergy to the test material's active or inactive ingredients
  3. Verbal confirmation of a diagnosed chronic inflammatory condition
  4. Verbal confirmation of the diagnosis of any autoimmune disease or immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis)
  5. Chronic consumption of oral anti-inflammatory medications such as cyclosporine for skin conditions such as psoriasis, dermatitis, rosacea
  6. Chronic consumption of anti-inflammatory medications or medications known to affect immune function on a daily basis, including medications for allergies and asthma with the exception of Ventolin, within 4 weeks of baseline visit (visit 2)
  7. Verbal confirmation of chronic recurring respiratory signs and symptoms due to allergies (including seasonal allergies) or chronic bronchitis
  8. Verbal confirmation of active shingles and/or herpes virus infections, within 2 months of baseline
  9. Use of medical marijuana including THC-free CBD (any form of consumption)
  10. Use of recreational marijuana (any form of consumption) within the past 4 weeks and is unwilling to stop use for the duration of the study
  11. Use of immunomodulators (including corticosteroids) such as immunosuppressant or immune-stimulant medications within 4 weeks of baseline
  12. Taking antibiotics within 2 weeks of screening
  13. Use of immune support supplements unless willing to undergo washout
  14. Use of multivitamins unless on a stable regimen for 3 months as assessed by QI
  15. Verbal confirmation of Type I or Type II diabetes or clinically important hepatic, cardiac, pulmonary, pancreatic, neurologic, or biliary disorder
  16. History or current diagnosis of renal disease with the exception of a history of kidney stones symptom-free for 1 year
  17. Cancer, except skin cancers completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
  18. Current or pre-existing thyroid condition. Treatment on a stable dose medication for 6 months will be reviewed on a case-by-case basis by the QI
  19. History of or current blood/bleeding disorders with the exception of a history of anemia caused by a deficiency of a mineral or vitamin, and no longer present.
  20. Verbal confirmation of the diagnosis of Hepatitis B/C positive
  21. Chronic unusual sleep routine (examples: irregular routine with frequent late nights, studying, partying)
  22. Use of Prebiotics and Probiotics unless on a stable regimen for 3 months as assessed by QI.
  23. Smoking study participants must be willing to abstain from tobacco use in the morning of a clinical visit
  24. High alcohol intake (average >2 standard drinks per day, or ≥15 standard drinks per week for men, or ≥8 standard drinks per week for women)
  25. Alcohol or drug abuse in the past year
  26. Blood donation during or within 30 days of the last study visit
  27. Subjects with unstable medical conditions as assessed by the QI
  28. Clinically significant abnormal laboratory results at screening as assessed by the QI
  29. Participation in a clinical research trial within 30 days prior to randomization
  30. Individuals who are cognitively impaired and/or who are unable to give informed consent
  31. Any other condition which in the QI's opinion may adversely affect the subject's ability to complete the study or its measures or which may pose a significant risk to the subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04144673


Locations
Layout table for location information
Canada, Ontario
KGK Science Inc.
London, Ontario, Canada, N6A 5R8
Sponsors and Collaborators
Natural Immunogenics Corp.
KGK Science Inc.
Investigators
Layout table for investigator information
Principal Investigator: David Crowley, MD KGK Science Inc.
Additional Information:
Publications:
Layout table for additonal information
Responsible Party: Natural Immunogenics Corp.
ClinicalTrials.gov Identifier: NCT04144673    
Other Study ID Numbers: 19SIHN
First Posted: October 30, 2019    Key Record Dates
Last Update Posted: April 23, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Natural Immunogenics Corp.:
Immune Support
Active lifestyle
Silver
Healthy Adults
Cold
WURSS